Nanobiotix (NBTX) said Monday its JNJ-1900 drug candidate showed a median overall survival of 23 months for certain patients with pancreatic cancer in a phase 1 study.
A historical review of 144 patients with locally advanced pancreatic cancer treated at the same center showed a median overall survival of 19.2 months, the company said.
The drug, jointly developed with Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceutica, also showed a favorable safety profile, Nanobiotix said.
The company added that the results prompted investigators to recommend further evaluation in a randomized study. The US Food and Drug Administration has also cleared researchers to expand the study to include a new cohort that has already recruited and dosed its first patient, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。